| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Revenue | ||||||
- | - | - | 0 | 0 | ||
General and administrative expenses | ||||||
7,664 | 6,310 | 5,412 | 3,931 | 1,287 | ||
Research and development expenses | ||||||
6,630 | 4,252 | 2,621 | 1,719 | 489 | ||
Total operating expenses | ||||||
14,295 | 10,563 | 8,034 | 5,650 | 1,776 | ||
Loss from operations | ||||||
-14,295 | -10,563 | -8,034 | -5,650 | - | ||
Other income (expense) | ||||||
Interest expense | ||||||
32 | 2,392 | - | - | - | ||
Debt extinguishments | ||||||
-1,831 | -1,408 | - | - | - | ||
Interest expense - Senior Secured Note | ||||||
- | - | 724 | 0 | - | ||
Change in fair value - Senior Secured Convertible Note | ||||||
558 | 903 | - | - | - | ||
Offering costs - issue of Senior Secured Convertible Notes | ||||||
550 | 614 | - | - | - | ||
Modification - Series Z Warrant Agreement | ||||||
- | 1,140 | - | - | - | ||
Modification - Series A-1 Warrant Agreement | ||||||
- | - | -222 | 0 | - | ||
Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series A-1 Warrants | ||||||
- | 349 | - | - | - | ||
Series W Warrants Exchange Offer - April 5, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series W Warrants | ||||||
- | 766 | - | - | - | ||
Unit Purchase Options (UPOs) Exchange Offer - August 22, 2018 - incremental fair value - UPO-Z issued-upon-exchange of UPO-W | ||||||
- | 2 | - | - | - | ||
Loss - Series A Preferred Stock Units private placement | ||||||
- | - | 3,124 | 0 | - | ||
Change in fair value - Series A Warrants derivative liability | ||||||
- | 96 | -1,942 | 0 | - | ||
Change in fair value - Series A Convertible Preferred Stock conversion option derivative liability | ||||||
- | -64 | -643 | 0 | - | ||
Other income (expense), net | ||||||
-2,972 | -7,609 | -1,485 | 0 | - | ||
Loss before provision for income tax | ||||||
-17,268 | -18,172 | -9,519 | -5,650 | - | ||
Provision for income taxes | ||||||
- | - | - | 0 | - | ||
Net loss - before noncontrolling interest | ||||||
-17,268 | -18,172 | - | - | - | ||
Net loss - before noncontrolling interest | ||||||
- | - | -9,519 | - | - | ||
Net loss attributable to noncontrolling interest | ||||||
-810 | -204 | - | - | - | ||
Net loss - attributable to PAVmed Inc. | ||||||
-16,457 | -17,968 | -9,519 | -5,650 | -1,776 | ||
Less: Series B Convertible Preferred Stock dividends earned | ||||||
269 | 203 | - | - | - | ||
Less: Series A-1 Convertible Preferred Stock dividends earned | ||||||
- | 25 | 79 | 0 | - | ||
Less: Series A Convertible Preferred Stock dividends earned | ||||||
- | 26 | 112 | 0 | - | ||
Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock | ||||||
- | 726 | - | - | - | ||
Series A and Series A-1 Exchange Offer - March 15, 2018 - increase to additional paid-in capital - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock | ||||||
- | -199 | - | - | - | ||
Deemed dividend Series A-1 Convertible Preferred Stock | ||||||
- | - | 182 | - | - | ||
Series A Exchange Offer - November 17, 2017 - deemed dividend - incremental fair value - Series A-1 Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock | ||||||
- | - | 504 | - | - | ||
Deemed dividend Series A-1 Convertible Preferred Stock issued in a private placement | ||||||
- | - | - | 0 | - | ||
Deemed dividend Series A-1 Convertible Preferred Stock issued in the Series A Exchange Offer | ||||||
- | - | - | 0 | - | ||
Net loss attributable to PAVmed Inc. common stockholders | ||||||
-16,727 | -18,750 | -10,398 | -5,650 | - | ||
Net loss per share - attributable to PAVmed Inc. - basic and diluted | ||||||
-0.54 | -0.81 | -0.71 | -0.44 | -0.16 | ||
Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted | ||||||
-0.55 | -0.84 | -0.77 | -0.44 | - | ||
Weighted average common shares outstanding - basic and diluted | ||||||
30,197 | 22,276 | 13,495 | 12,972 | 11,278 | ||